CTRI/2012/01/002324招募中3 期
The Investigation of FH0210 (Carbohydrate Derived Fulvic Acid in a Formulated Wellness Drink) for Self Medication to Prolong Pre-Art Phase in HIV Positive Subjects
Vihoton Pty Ltd0 个研究点目标入组 460 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female outpatients aged 18 years and over.
- •Subjects must give consent to participate in the study. All subjects must understand all aspects of the protocol and must receive a signed copy of the informed consent document.
- •Subjects must be known and confirmed HIV-1 positive who are healthy or present at most with stage 1 or 2 disease (according to WHO criteria in Appendix C) with a CD4 count between 250 cells/mm3 and 550 cells/mm3. Country specific guidelines will determine the CD4 count for inclusion i.e. 250 cells/mm3 in India and 350 cells/ mm3
- •Subjects must be ART-naïve (including subjects who received less than 1 month continuous ART more than 1 year ago).
- •Females of childbearing potential are eligible if they are not sexually active or if they follow a medically accepted contraceptive method (e.g. hormonal birth control for at least 2 months prior to the start of the study). Sexually active male and female subjects may also use two barrier methods or one barrier method with a spermicide, or an intrauterine device.
- •Subjects must be able to complete the questionnaire and understand all aspects pertaining to the study as to discuss it with the study investigator. Note: if a subject is illiterate, the site counsellor / Investigator may discuss the questions with the subject and may provide the responses however, the counsellor/ Investigator may not answer for the subject. The counsellor / Investigator must also be available at all study visits and must be blinded to the treatment group. (The presence of the third party must be consented to and noted as such in source)
- •Subjects must be otherwise healthy with no other systemic disease that can influence the immune response, e.g. cancer, psoriasis, rheumatoid arthritis etc.
- •The liver enzyme markers (AST and GGT) of the subject should be within twice the upper limit of the normal country/lab specific range.
- •A negative urine pregnancy test must be confirmed
- •Subjects must be willing to comply with all scheduled visits and procedures
排除标准
- •Pregnancy or breast/feeding or sexually active women not using medically accepted contraceptive method.
- •Systemic uncontrolled diseases such as cancer, psoriasis, diabetes mellitus, kidney failure, liver failure, auto-immune diseases, haematologic diseases, GIT conditions, cardiovascular or lung disease which significantly compromise the subjectsâ?? health and any immune system disease other than atopy (e.g. hay fever).
- •Chronic diarrhoea that may lead to malabsorbtion.
- •Malignancies that require therapy.
- •Acute or chronic HIV related opportunistic infection which may mandate initiation of ART therapy.
- •Subjects with psychiatric diseases or deviations.
- •CD4 count at baseline of less than 250 cells/mm3 or 350 cells/mm3 (Country specific i.e. 250 cells/ mm3 in India and 350 cells/ mm3 in South Africa.)
- •Haemoglobin level of lower than 8 g/dL.
- •Abnormal levels of proteinuria of not more than 1gram per day or serum creatinine that is considered clinically significant.
- •Liver enzyme markers of the subject more than twice the upper limit of the normal range.
- •Active alcohol or substance abuse i.e. clinically significant.
- •Medications prohibited throughout the study, including herbal medications, (including products such as St. Johnâ??s Wort), and other immunosuppressant such as cyclosporine and systemic corticosteroids etc. Please note that topical and inhaled corticosteroids are permitted.
- •Subjects that already use CHD-FA for self medication.
- •Subjects must not have used any fulvic acid products within in the previous 3 months.
- •The inability to tolerate oral medication
- •Expected non-compliance
- •Subjects not able to give informed consent
- •Subjects not able to document or fill in/record symptoms on a diary card.
- •(If a subject is illiterate, this exclusion is not applicable under the following circumstance:
- •Where a family member has completed the Diary card on behalf on the Subject
- •The Diary Card completion is verified by the site counsellor who may discuss the questions with the subject and may provide the responses not already completed however, the counsellor may not answer for the subject. The counsellor must also be available at all study visit and must be blinded to the treatment group)
- •Subjects already included in another study
- •Subjects related to investigators or in their employ
研究者
相似试验
尚未招募
不适用
The association between a modified carbohydrate diet, quality of life and glycaemic control in Australian adults with type 1 diabetes mellitus: A pilot studyType 1 Diabetes MellitusACTRN12619001676101Gold Coast University Hospital23
尚未招募
3 期
Comparing carbohydrate derived fulvic acid and ethylenediamine tetraacetic acid on time taken to locate calcified root canalsCTRI/2023/08/056203SRM DENTAL COLLEGE
Unknown
2 期
The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple TherapyHelicobacter PyloriNCT00281047Hamamatsu University138
已完成
不适用
Fermentable dietary carbohydrates as triggers of functional gut symptoms in patients with inflammatory bowel diseaseInflammatory bowel disease (Crohn?'s disease and ulcerative colitis)Digestive SystemNoninfective inflammatory bowel diseaseISRCTN98226923King's College London (UK)32
进行中（未招募）
不适用
PREMETHEP : Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an early predictive factor of overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.Hepatocellular carcinoma (HCC) is the 3rd cause of death by cancer. For patients with inoperable advanced HCC, systemic therapy with Sorafenib (Nexavar®) is the only therapeutic with proven survival benefits. However, the efficacy of Sorafenib remains inconstant and the overall incidence of treatment-related adverse event is 80%.MedDRA version: 18.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2015-004108-44-FRCentre Georges-François Leclerc87